• The partnership will help InsuraGuest’s coverage potentially reach more than 9,300 hospitality customers in the United States and Canada by the middle of 2021
• Hospitality Liability coverage allows covered properties to transfer certain liabilities, lowering claim ratio and risk profiles
• InsuraGuest’s product can also help properties generate revenue by keeping a percent of the nightly software fee

Innovative insurtech leader InsuraGuest Technologies (TSX.V: ISGI) (OTC: IGSTF) has sealed a premier preferred partnership with leading global insurance brokerage Hub International Limited (“HUB”), to provide InsuraGuest’s Hospitality Liability coverage to properties in Hub International’s portfolio. Signed via wholly owned subsidiary InsuraGuest, the deal will help HUB hotel clients significantly lower their insurance premiums, transfer small property and medical guest claims as well as generate additional revenue (https://ibn.fm/AYcJB).

The coverage will start with HUB clients in the United States, with the goal of expanding to Canadian hotel clients by the middle of 2021. According to InsuraGuest CEO and Chairman Douglas Anderson, the premier preferred partnership with HUB will allow the company to expand its product offering to more than 9,300 hospitality customers in the U.S. this year and into Canada in 2021.

The InsuraGuest Hospitality Liability coverage will allow HUB hotel clients to benefit from an extra layer of protection in case a guest experiences an accident, in-room property damage, accidental medical and death and dismemberment or theft while staying at an InsuraGuest-covered property.

Currently, InsuraGuest integrates with approximately 70 different property management systems through the proprietary API. The integrated use allows for the organization to transfer liabilities that fit specific criteria to the InsuraGuest carrier. The transfer of these liabilities to the InsuraGuest Hospitality Liability coverage enables hotel properties to lower their risk profile and claim ratio, thus decreasing General Liability premiums.

Most of a hotel client’s claims are from a small property or medical claim, which frequently gets applied to the General Liability coverages. With InsuraGuest, the risk is transferred from the hotel client through the small fee applied per night to the guest’s bill. InsuraGuest will then pay these small claims, keeping them off the hotel client’s General Liability policy.

The higher frequency of claims drives up the premiums paid by a hotel client for their General Liability policy coverage. With the transfer to InsuraGuest, the hotel client presents less risk for their general liability policy, lowering premiums.

In addition, hotels properties using InsuraGuest’s product will be able to generate additional revenue through the platform’s implementation. When a hotel offers the InsuraGuest Hospitality Liability coverages, an automatic charge is placed on their folio or bundled into their resort/amenity/urban fee upon check-in. The fee for coverage and software is $4.95 a night.

“Given the current state of the hospitality industry, it is nice to have a new and exciting tool such as InsuraGuest, which will help us lower a hotel’s overall liability costs through claims avoidance,” said Kevin Eggleston, the Managing Director of HUB’s Hospitality Specialty Practice. “InsuraGuest costs a hotel owner nothing. In fact, it actually generates new revenue while giving us the means to reduce General Liability premiums by improving guest loss ratios. By minimizing the frequency of a hotel’s claims, we are able to have better underwriting conversations with the marketplace.”

The hospitality industry is only one of the sectors InsuraGuest serves. The company’s goal is to disrupt the insurance landscape by utilizing its proprietary software platform to deliver digital insurance to multiple sectors. The company aims to transform the way insurance is delivered with the revolutionary idea that insurance should be bought, not sold.

For more information, visit the company’s website at www.InsuraGuest.com.

NOTE TO INVESTORS: The latest news and updates relating to ISGI are available in the company’s newsroom at http://ibn.fm/ISGI

• Clinical-stage biotech developer CNS Pharmaceuticals is working to demonstrate the potential effectiveness of its novel drug, Berubicin, in treating aggressive and rare brain cancer glioblastoma multiforme (“GBM”)
• CNS expects to launch Phase II trials of Berubicin later this year or in Q1 of 2021, building on promising results shown in initial trials
• One patient in the Phase I trial has remained cancer-free over the course of 14 years, and 44 percent of the patients who could be evaluated experienced a clinically significant positive response to Berubicin
• CNS’s laser-focused strategy for developing a GBM therapy is also leading the company to prepare, through its sub-licensee partner WPD Pharmaceuticals, for a first-ever Phase I pediatric trial of Berubicin in Poland as well as continuing the development of the company’s second drug candidate, WP1244, which has shown tremendous promise in stopping cancer proliferation in preclinical studies comparing it to chemotherapy drug daunorubicin

CNS Pharmaceuticals (NASDAQ: CNSP) is building its technologically advanced strategy for demonstrating the potential brain tumor-fighting capabilities of its novel drug Berubicin, announcing recently an agreement with medical imaging company Image Analysis Group (“IAG”) to evaluate upcoming clinical phase II patient trial scansin real time.

IAG’s proprietary platform DYNAMIKA is an AI-driven technology developed to aid in the analysis of patient responses during pharmaceutical trial’s, and IAG has extensive experience in partnering with the biotech industry — oncology companies in particular — to provide a centralized reading of critical data, according to a news release about the partnership (https://ibn.fm/7OTsk).

CNS Pharmaceuticals is developing unique treatments for primary and metastatic cancers of the brain and central nervous system, including the company’s lead drug candidate Berubicin, which aims to treat the aggressive brain cancer glioblastoma multiforme (“GBM”) (https://ibn.fm/4r5U3).

“This drug was designed specifically to penetrate the Blood-Brain Barrier and to treat cancers in the brain, which we all know are extremely difficult given that the brain is the most privileged organ in the body,” CNS CEO John Climaco told attendees at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit as part of the company’s investment highlights presentation at the virtual conference Sept. 22 (https://ibn.fm/AzZv6).

During a 2006 Phase I clinical trial, Berubicin “appeared to demonstrate one durable, complete response against GBM,” Climaco said. The specified patient has remained cancer-free as of the last assessment on Feb. 20 of this year. Twenty-seven of the participating patients were able to be evaluated, and 44 percent of them experienced a clinically significant improvement in condition as a result of the trial.

Regarding IAG’s scientific and clinical imaging expertise in the field of GBM and the prowess of the company’s analytical API, Climaco stated, “IAG has an exemplary track record of partnering closely with companies in the biotech space to provide critical analysis of both efficacy and patient response, which we believe will be pivotal in advancing our Berubicin clinical trials.”

IAG CEO Dr. Olga Kubassova stated the platform will not only help CNS analyze Berubicin’s effectiveness and build scientific evidence of its performance but will also help the company efficiently reduce development costs, uncertainties about outcomes and timelines for the product’s advancement.

In addition to the Berubicin trials, CNS and its partner WPD Pharmaceuticals are preparing for a first-ever Phase I Berubicin trial for pediatric patients who have brain cancer. CNS is also developing a second drug candidate, WP1244, shown in preclinical studies to have a DNA-binding agent 500 times more potent than chemotherapy drug daunorubicin in stopping tumor cell expansion.

“We are laser-focused as a company at this point on a critical unmet medical need, and that is the treatment of glioblastoma, which is the most aggressive, common and incurable form of brain cancer,” Climaco told conference attendees. “If you get glioblastoma, the devastating fact is you’re going to die from that disease. After decades without progress in the treatment of this terrible disease, we believe that Berubicin could potentially be a game-changer.”

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Pharmaceutical services innovator Trxade Group Inc. has gained investor attention as it has emerged as a responsive healthcare market force during the ongoing COVID-19 pandemic
• As the pandemic began to unfold earlier this year, Trxade Group saw revenues jump effectively to three times their previous Q1 level, largely as a result of personal protective equipment products
• The company’s core mission has been to help small, community-centered retail pharmacies compete with large national chains through prescription drug price transparency and AI-driven protocols that help pharmacies stay abreast of what’s available
• Trxade Group’s advances in delivering services ranging from consultation to drug shipping via virtual, remote-access technology has kept it abreast of developments as the effects of the pandemic have led to social-distancing limitations

The surprise manifestation of the novel COVID-19 coronavirus and its spread as a global pandemic this year has led to a cascade of changes involving how health care is administered, perhaps most notably in the increased adoption of telehealth services.

Telehealth services have been ideally situated for meeting remote access needs amid conditions in which the potential spread of a highly contagious virus has led medical policy makers to discourage close contact between people and gatherings in large numbers, especially indoors.

Five hundred healthcare industry executives surveyed by marketing agency Boston Digital recently reported the growing use of telehealth amid the pandemic has delivered largely positive results and the majority of the respondents said some of the changes in care protocols would undoubtedly remain in effect after the pandemic ends (https://ibn.fm/wTD8S).

Integrated pharmaceutical services innovator Trxade Group (NASDAQ: MEDS) has seen growing enthusiasm about its business profile during the course of the pandemic, largely because of revenue growth that has far exceeded expectations. The Q2 report showed a more-than-triple increase year-over-year to $6.6 million, practically tripling sequentially after Q1 this year as reported in a July earnings call (https://ibn.fm/KNVJs), which sent the stock soaring 35 percent immediately after the announcement, as noted in a Q3 research summary (https://ibn.fm/vBuoV).

The company’s artificial intelligence API is designed to streamline the transfer of information between healthcare industry businesses. Trxade’s model thereby helps smaller, independent pharmacies in particular to competitively serve patients in spite of the proliferation of large pharmaceutical chains.

But Trxade is also rolling out a first-of-its-kind bundled service that combines telehealth performance, a COVID-19 risk assessment tool and a personal protective equipment (PPE) purchasing tool. The bundled service will help businesses better deal with the medical needs of their internal corporate structures during the changing conditions as well as once the pandemic conditions have ended.

Trxade has been working to build its capital since uplisting to the Nasdaq exchange earlier this year (https://ibn.fm/C4wWa) and more recently gaining inclusion on this year’s Russell’s Microcap Index (https://ibn.fm/2120T). The company has also brought international investor relations specialists MZ Group on board to expand the company’s strategic investor relations program across all key markets.

The growing brand in the medical technology space has attracted nearly 11,700 independent pharmacies to its network — more than 50 percent penetration among the United States’ estimated 22,000 independent pharmacies.

“Our platform lets these independents know that they’re receiving a fair price from competing suppliers on fair payment terms and often with next day delivery,” Founder, Chairman and CEO Suren Ajjarapu said during the earnings conference call. “We believe this radical price transparency, economy of scale and competition amongst suppliers leads (to) up to 10% reduction in pharmacies’ total annual drug purchase costs, with a drug-level savings of up to 90% on certain pharmaceutical products.”

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

• SGMD has filed updated Form 8K Current Report with SEC
• Filing includes information about issues related to company’s status, including planned expansion of BudCars cannabis-delivery service
• Sugarmade sees “major business opportunities out of both sites once operations begin”

Sugarmade (OTCQB: SGMD), a product and branding marketing company investing in operations and technologies with disruptive potential, has released the publication of a Form 8K Current Report filing with the United States Securities and Exchange Commission (“SEC”) (https://ibn.fm/Ngrsg). The filing includes specific information about several issues related to the company’s performance and outlook, including planned expansion of the BudCars cannabis delivery service.

According to the filing (https://ibn.fm/wzDZ4), the highly successful Sacramento, California-based BudCars, which has reported record sales for the past several months (https://ibn.fm/YWib6), has plans to open two hubs in Los Angeles in the coming months.

“One of the Los Angeles sites is behind schedule, and the other is well ahead of schedule,” the filing reported. “We still expect both to become operational as soon as final issues are resolved.” Sugarmade, which has a 40% interest in BudCars with an option to purchase a controlling interest, noted that last-minute regulatory issues were causing some delays in opening of the first location.

“The first of these expansions was expected to go online during July, and significant progress toward opening has taken place,” the filing noted. “Unfortunately . . . we are still working to get the security plan approved by local authorities, and we have a few minor issues relative to facilities build-out concerning the Americans with Disabilities Act (‘ADA’). As soon as these final issues are cleared, we plan to begin operations.”

“On the positive side, we are ahead of schedule at the other Los Angeles site,” the report continued. “We are happy to report the turn-up of this second site could occur sooner than was expected. Of course, we see major business opportunities out of both sites once operations begin. We will be sure to keep everyone updated. We are working hard daily on both sites.”

The filing noted that the cannabis delivery trend is growing substantially. “This is resulting in increases in the number of new customers and in the average sale size on a per-delivery customer basis,” the filing concluded. “We see cannabis delivery continuing to accelerate. Certainly, the Los Angeles market is especially robust relative to delivery services.”

BudCars is a retail business that offers same-day delivery of top-quality cannabis. Customers choose from a variety of products, including edibles, flower, pre-rolls, vapes, tinctures and concentrate across dozens of premium brands. Once consumers complete their purchases online, they receive their order the same day via BudCars Cannabis Delivery Service.

Sugarmade Inc. is a product and branding marketing company investing in operations and technologies with disruptive potential. In addition to its financial interest in the BudCars brand, SGMD’s brand portfolio includes CarryOutsupplies.com and SugarRush(TM).

or more information, visit the company’s website at www.Sugarmade.com.

NOTE TO INVESTORS: The latest news and updates relating to SGMD are available in the company’s newsroom at http://ibn.fm/SUGAR

• Rritual’s suite of premium functional mushroom and adaptogenic elixirs is designed to offer various health benefits, such as increased immunity, cognitive function, stress management and more
• The company’s products are expected to be available online through Rritual’s site and Amazon by fall 2020
• The Rritual team has extensive ties and influential relationships with leading retail businesses, providing a wide market for growth
• The functional mushroom industry has no clear and dominant leader, allowing Rritual to target this role with its premium products. Rritual is currently the only premium brand on the market
• The global functional mushroom market is expected to exceed $50 billion by 2025, putting Rritual in the position for success
• Functional mushroom demand is expected to rise from $23 billion to $34 billion by 2024

Rritual Mushrooms is a private company founded in 2019, whose declared purpose is to help people meet the demands of modern life with style and ease by incorporating functional mushrooms, adaptogens and superfoods into their diets.

The company manufactures premium plant-based products such as small-batch elixir powders, and each product features mindfully selected medicinal mushrooms and adaptogenic herbs. Pursuing customers with various need-states, Rritual offers products that fit every lifestyle.

Suite of Premium Rritual(TM) Products

Rritual recently announced the launch of its suite of premium functional mushroom and adaptogenic elixirs. These elixirs were developed by a leading team of scientists, doctors and experts across the wellness industry, under the guidance of Rritual President Dr. Mike Hart.

The initial product line includes:

• Chaga (immune booster) – Full of bioactive polysaccharides, Rritual’s Chaga blend combines the Chaga mushroom with Eleuthero root for optimal immune system benefits.
• Lion’s Mane (brain booster) – Designed to support cognitive function and brain health, Lion’s Mane is paired with Rhodiola root. The elixir can also help the body manage stress.
• Reishi (stress support) – Rich in polysaccharides, triterpenes, amino acids and fatty acids, the Reishi blend is infused with Ashwagandha root. This combination aims to help the body and mind fight anxiety, with long term effects that may improve quality of sleep for those with restless minds.

“The health and wellness benefits of mushrooms and plant-based therapies are backed by decades of scientific research. Rritual’s new line of elixirs embraces that research and provides consumers with an easy way to get a daily dose of the powerful effects,” Hart said in a news release.

Rritual CEO David Kerbel noted that the company is proud to bring together age-old mushroom consumption practices and data-backed research to create new formulas that meet the needs of modern consumers. “Whether to relieve stress, increase mental output or boost immunity, we want to be a trusted and effective component of a consumer’s daily health and wellness routine,” he added.

Rritual Timeline

According to its investor presentation, Rritual has already fulfilled most of the milestones it set for Q1 and Q2 2020 as part of its growth and development timeline. So far, the company has completed formulation R&D, product line development, test marketing, brand development, logistics partnerships and agreements, initial distributor partnerships, seed financing and the phase one launch of its product suite.

Rritual E-Commerce Rollout Strategy

The company’s strategy for e-commerce rollout success consists of direct-to-consumer (D2C) sales through the use of multiple online platforms and through team connections to facilitate rapid expansion within the market.

In the first stage, Rritual will use its own website and Amazon to facilitate its D2C initiative, followed by leveraging its team connections to sell products through planned specialty e-commerce channels such as Costco, CVS, Walmart, and Vitacost using preexisting relationships.

Brick-and-Mortar Rollout Strategy

Using partnerships already in place with The Jet Collective and leveraging the preexisting connections of its team for direct discussions with global retail brands, Rritual’s brick-and-mortar strategy features a two-stage rollout that targets 15 leading retailers.

In the first stage, Rritual aims to launch with four non-competing chains, while utilizing best practice agreements (320 Sprouts stores, 330 H-E-B stores, 240 Meijer stores and 1,600 Publix stores). In stage 2, distribution is expected to advance to additional retail establishments (100 Wegmans stores, 77 Fresh Thyme stores, 440 Whole Foods stores, 120 Shaw’s stores, 400 Stop & Shop stores, 300 Wakefern/Shoprite stores, 610 Vitamin Shoppe stores, 90 Bartell Drug stores, 40 Giant Eagle market district stores and 1,800 Target stores), while collaboration with Kroger will take place within two sub-markets (300 Ralphs stores and 120 Harris Teeter stores).

Market Growth Outlook

As it is yet in its early stages, the functional mushrooms market is rife with opportunities for growth. At this time, no dominant brand is in place, and there remains an absence of a premium brand to lead the category.

The entire functional food market is currently valued at more than $275 billion, with global shifts supporting wellness and a 7.9% CAGR forecast through 2025. Demand for functional mushrooms is also growing, with a forecast rise from $23 billion to $34 billion by 2024 as a result of growing popularity due to the superfood’s unique properties that have been shown to boost immunity, cognitive function and more. The worldwide functional mushroom market is projected to exceed $50 billion by 2025, with recent data indicating an increase in demand for key mushroom varieties of up to 800%.

Management Team

David Kerbel, CPC, is CEO of Rritual and has over 30 years of senior experience in retail, brokerage and CPG industries. From 2008 to 2011, Kerbel served as Senior Vice President of Sales for Celsius Holdings Inc., helping that company achieve a number of important milestones. During his tenure, Celsius grew its retail sales from $400,000 to a multimillion-dollar figure, developed nationwide representation with CROSSMARK Inc. and established distribution with industry giants such as 7-Eleven, Ralph’s, C&S, Costco, BJ’s Wholesale, CVS, Walgreens, Walmart, Rite Aid, Target, Duane Reade and Stop & Shop. In total, Celsius’ new distribution stemming from Kerbel’s direct efforts led to $36 million in incremental sales in 2010 alone. He also implemented new procedures that led to a 10 percent reduction in operating expenses. Kerbel brings tremendous experience to the Rritual team, as well as vital relationships with industry leaders such as Walmart, Costco, Kroger, Walgreens, CVS, 7-Eleven, Safeway, Publix, Sprouts and more.

Warren Spence is the COO and a Director of Rritual. He has over 25 years in the food and beverage industry. His roles within the industry have included senior positions with brands like Red Bull and Olivieri. His specialization is in supply chain and operations systems. He was appointed Head of Supply Chain for Nude Beverages in 2019.

Dr. Mike Hart, MD, is the President of Rritual. His work has been published in peer-review journals about therapies involving cannabis and ketamine. His outspoken stance on these subjects landed him an appearance on the Joe Rogan Experience Podcast in 2019. On-air, he discussed the use of psychedelic medicines as a treatment for mental health conditions, including PTSD.

Stacie Gillespie is CCO and Director of Formulations for Rritual. She has over 25 years of leadership in the branding and product strategies used by wellness companies. She has leveraged this expertise for companies such as Aura Cacia, MegaFood and Gaia Herbs. She is the creator of multiple award-winning consumer health products.

Sarton Molnar-Fenton is Vice President of Sales-USA for Rritual. She started her career with Vitamin Water, with other large companies under her belt, including Danone, as a District Manager. She worked with Nestle on its Tribe Hummus brand and played an integral part in relaunching the brand, gaining category share and establishing product development partnerships with companies like Trader Joe’s. She also played a key role in launching the Hydralyte brand in the United States.

Scott Naccarrato is the company’s Vice President of Sales-Canada. He is experienced in sales with a deep connection in retail. Recently, he worked with Nutiva, assisting in the pioneering of Organic MCT oil, healthy fats and the plant-based protein categories. He is data-oriented in his approach, which has resulted in over $100 million in sales and double-digit year-over-year growth for the brands of which he has been a part.

For more information, visit the company’s website at www.WeAreRritual.com.

• Research shows psilocybin produces immediate, substantial and sustained improvements in anxiety and depression
• Global medicinal mushroom market projected to increase by almost $14 billion annually for the next several years
• Pure Extracts is a plant-based extraction company with new vertical in the mushroom space

Recent groundbreaking research indicates that psilocybin-assisted psychotherapy may be effective in treating depression, a debilitating disorder that plagues an estimated 300 million people in the United State. Psilocybin is the main psychoactive ingredient in “magic” mushrooms. With growing interest in the mushroom sector — both psychedelic and functional — companies such as Pure Extract Technologies could see exciting growth and expansion in the future.

A recent National Centre for Mental Health (“NCMH”) article reported that “a small number of studies have been conducted trialing psilocybin on patients with treatment-resistant depression. A person may be defined as having treatment-resistant depression if their symptoms of major-depressive disorder do not subside with attempted treatment from two different classes of antidepressants.”

Results of the tests showed that, after only one week — as well as after three months — depression scores significantly decreased, with the majority of participants experiencing reduced depression severity after three months. That initial test sparked intense interest, and “further research has been conducted with similar findings of efficacy,” the article noted.

“In [a] Johns Hopkins psilocybin research project, they found that 80% of healthy volunteers that returned a month after having one or two doses of psilocybin reported that the experience of taking the drug was in their top five meaningful experiences they’d ever had,” the article continued. “Around 90% reported increased positive mood and greater life satisfaction.” The report goes on to note that additional psilocybin studies have shown that for those with anxiety and patients with life-threatening cancer, the drug produced immediate, substantial and sustained improvements in anxiety and depression.

Pure Extract Technologies recognizes that psychedelic and functional mushroom industries are among the fastest-growing in North America, with the global medicinal mushroom market projected to increase by almost $14 billion annually for the next several years. As the industry transitions to meet these burgeoning needs, few companies appear to be prepared for the new opportunity.

Pure Extracts, however, is a private, plant-based extraction company with a new vertical in the mushroom space. The savvy company is ideally positioned to become a dominant extraction company in the space and a leader in the rapid development and commercialization of functional and medicinal products.

Pure Extracts is focusing on a strategic business model consisting of three verticals: in-house brands; toll processing, offering contract cannabis and hemp processing to Canadian Licensed Producers and international partners to distribute under their own brands; and white labelling, or supplying products in consumer-ready packaging for companies licensed to sell cannabis oil extracts and for CPG brands seeking licensed cannabis manufacturing partners.

Pure Extracts is positioned to enter the commercial cannabis sector, as well as a new vertical in functional mushrooms, as an experienced producer. Led by a team of qualified experts and providing cutting-edge CO2 extraction technology, the company is set up for long-term strategic distribution and product innovation.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to Pure Extract Technologies are available in the company’s newsroom at http://ibn.fm/Pure

• VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders
• Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety disorder, major depressive disorder and neuropathic pain.
• The global CNS therapeutics market is estimated to reach $130 billion by 2025
• The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year
• VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care in large markets for treatment of anxiety, depression and other central nervous system (“CNS”) disorders, potentially addressing the unmet needs of millions worldwide
• The company’s efforts are advanced by a skilled management team with decades of experience in biotechnology, pharmaceuticals, CNS drug development and more

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders.

The company is headquartered in South San Francisco, California, the “Birthplace of Biotechnology,” among the largest cluster of biotechnology companies in the world.

New Generation Medications

VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of VistaGen’s three drug candidates offers significant commercialization potential in multiple large CNS markets.

PH94B

Fast-acting (10-15 minutes), non-systemic and non-sedating in Phase 2 clinical studies, PH94B is a first-in-class neuroactive nasal spray that, administered in microgram doses, binds to chemosensory receptors in the nasal passage that trigger neural circuits responsible for suppressing fear and anxiety caused by stressful social or performance situations.

PH94B is currently being developed as an acute treatment of anxiety in adults with Social Anxiety Disorder (“SAD”). In December 2019, PH94B became the first drug candidate to be granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for development of a treatment for SAD, positioning it to potentially become the first FDA-approved fast-acting acute treatment for adults with the anxiety disorder, if planned Phase 3 studies are successful.

A successful Phase 2 program has been completed, and, after achieving consensus with the FDA in mid-2020 that the design of its Phase 3 studies of PH94B in SAD may mirror the design of the highly statistically significant (p=0.002) Phase 2 public speaking study of PH94B in SAD, the company’s preparations for pivotal Phase 3 clinical development of PH94B are underway.

To support Phase 3 development and commercialization of PH94B for anxiety disorders in large anxiety disorder markets in Asia, VistaGen recently entered into a strategic licensing and collaboration agreement with EverInsight Therapeutics, a company formed and currently funded by a large global venture capital firm, CBC Group. The company received a $5 million non-dilutive upfront license payment from EverInsight in August 2020. If Phase 3 development is successful, VistaGen is eligible to receive additional development and commercial milestone payments of up to $172 million, plus tiered royalties on sales of PH94B in Greater China, South Korea and Southeast Asia. VistaGen retains exclusive rights to develop and commercialize PH94B in all other markets.

VistaGen is also assessing potential Phase 2A clinical development opportunities to evaluate PH94B in a range of other anxiety disorders, including:

• Adjustment Disorder with Anxiety
• Generalized Anxiety Disorder
• Postpartum Anxiety
• Perioperative Anxiety
• Panic Disorder
• PTSD

PH10

PH10 is an investigational fast-acting synthetic neuroactive nasal spray with therapeutic potential in a wide range of neuropsychiatric indications involving depression and suicidal ideation. VistaGen is initially developing PH10 as a potential fast-acting, non-sedating, non-addictive new generation treatment of major depressive disorder (“MDD”).

Upon self-administration, a microgram-level dose of PH10 sprayed into the nose binds to nasal chemosensory receptors that, in turn, activate neural circuits in the brain that lead to rapid-onset antidepressant effects, without side effects, systemic exposure or safety concerns that may be caused by FDA-approved drug treatments for MDD, including oral antidepressants and intranasal esketamine.

In a published exploratory Phase 2A MDD study, PH10 demonstrated rapid-onset and sustained antidepressant effects without the serious psychological side effects and safety concerns of ketamine-based therapy.

Following successfully completed Phase 2A development of PH10 for MDD, the company is currently preparing for a Phase 2B program in MDD.

VistaGen is also assessing the potential for Phase 2A clinical development of PH10 in a range of other depression-related indications, including:

• Postpartum Depression
• Treatment-resistant Depression
• Suicidal Ideation

AV-101

Part of a class of new generation investigational medicine in neurology and neuropsychiatry known as N-methyl-D-aspartate receptor (“NMDAR”) modulators, AV-101 is an oral prodrug of 7-chloro-kynurenic acid (7-Cl-KYNA), a potent and selective NMDAR glycine site antagonist. This drug candidate has the potential to serve as an innovative treatment for MDD and multiple neurological indications where current therapies are unsatisfactory.

VistaGen is currently evaluating AV-101, in combination with FDA-approved probenecid, in a range of neuropsychiatric and neurological indications, with both MDD and Neuropathic Pain already granted Fast Track designation by the FDA. The company is assessing the combination for a potential Phase 1B study to support a potential Phase 2A program in one or more of the following indications:

• Major Depressive Disorder
• Neuropathic Pain
• Levodopa-induced dyskinesia associated with Parkinson’s disease therapy
• Epilepsy
• Suicidal Ideation

CNS Therapeutics Market Outlook

The global CNS therapeutics market is estimated to reach $130 billion by 2025. The market was valued at approximately $82.3 billion in 2017 and is anticipated to grow at a healthy CAGR of more than 5.93% from 2018 to 2025. Even before the onset of the anxiety- and depression-provoking stressors from the COVID-19 pandemic, this growth was expected to be driven by a rise in mental illnesses and increased awareness of psychiatric disorders (https://ibn.fm/TonuU) – all likely to be amplified by the diverse impacts of the pandemic.

The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year. The impact of these conditions is particularly devastating among the young. Industry data suggest that approximately 20% of the world’s children and teens are affected by mental health conditions, and suicide is the leading cause of death among 15- to 29-year-olds (https://ibn.fm/4yY4d).

VistaGen’s mission is to help address the unmet needs of patients suffering from CNS disorders whose current treatments are either inadequate or generate debilitating side effects and serious safety concerns, including risk of abuse and death.

“Now more than ever, the new generation anti-anxiety and antidepressant medications we are developing at VistaGen – PH94B, PH10 and AV-101 – are relevant, necessary and demand the highly-focused and passionate efforts of our team and partners, with the support of our stockholders, to advance them to patients whose lives are disrupted by anxiety and depression disorders,” VistaGen CEO and Director Shawn K. Singh said in his closing remarks at the company’s 2020 Annual Meeting of stockholders.

Management Team

Shawn K. Singh, J.D. is the Chief Executive Officer and a Director of VistaGen. He has served on the company’s board of directors since 2000. He has nearly 30 years of experience serving in numerous senior management roles across multiple industries, including private and public biotechnology, pharmaceuticals, medical devices, venture capital, contract research and development, and law. Singh has a B.A. with honors from the University of California – Berkley. He has a J.D. degree from the University of Maryland Carey School of Law. He is also a member of the State Bar of California.

1. Ralph Snodgrass, Ph.D., is the Founder, Chief Scientific Officer and Director of the company. Snodgrass has more than 20 years of experience in the biotechnology field as a senior manager. He is recognized as an expert in stem cell biology, with over 28 years of experience using stem cells as biological research tools to promote development and drug discovery. He received a Ph.D. in immunology from the University of Pennsylvania. Snodgrass has published over 50 scientific papers with more than 17 patents and a number of patent applications.

Mark A. Smith, M.D., Ph.D., is VistaGen’s Chief Medical Officer He has over 20 years of pharmaceutical industry experience, primarily with CNS drug development. Smith has been a successful leader in the discovery and development of approximately 20 investigational new drugs. He has been a part of numerous CNS-related clinical trials. Smith received a bachelor’s and Master of Science from Yale University and a Doctor of Medicine and Doctor of Philosophy in Physiology and Pharmacology from the University of California – San Diego. He completed his residency in the psychiatry department at Duke University Medical Center.

Jerrold D. Dotson, CPA, is the Vice President, Chief Financial Officer and Secretary of VistaGen. He has over 25 years of experience in senior management positions in finance and administration at both public and private companies. Dotson is a licensed CPA in California and received his B.S. degree (Cum Laude) in business administration with a concentration in accounting from Abilene Christian College.

Mark A. McPartland is the company’s Vice President of Corporate Development and Investor Relations. He has over 20 years of experience in senior management roles in corporate development and investor relations at both public and private companies. McPartland received his Bachelor’s in business administration and marketing from Coastal Carolina University.

For more information, visit the company’s website at www.VistaGen.com.

NOTE TO INVESTORS: The latest news and updates relating to VTGN are available in the company’s newsroom at https://ibn.fm/VTGN

• The company’s current independent pharmacy member base represents over 50% of the United States pharmaceutical market within that vertical
• Actively used in all 50 states with over 11,700 pharmacies in its network, serving around 15 million patients indirectly through these networks of pharmacies

Pharmaceutical supplies and services provider Trxade Group (NASDAQ: MEDS) benefited from an increased exposure to potential investors in September, by attending several virtual investor events and conferences, where it was given the opportunity to present its innovative platform and its advantages for pharmacy members.

The company started the last month of the third fiscal quarter strong by attending the LD 500 Virtual Investor Conference, held September 1-4. During a presentation on September 2, Trxade CEO Suren Ajjarapu focused on the company’s prescription affordability efforts and its commitment to helping pharmacies met their customers’ needs while remaining profitable.

Following the LD Micro event, Trxade attended the 2020 Colliers Institutional Investor Conference on September 10 and the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16. Mr. Ajjarapu was available for one-on-one meetings during both events and hosted a virtual presentation during the Wainwright convention on September 16.

Such investor events can help Trxade further raise the profile of its supply chain trading platform that offers independent pharmacies nationwide access to the best supplier prices for prescription drugs. Currently, the company has an established presence in all 50 states, with over 11,700 pharmacies in its network. The company is indirectly serving around 15 million patients via these independent pharmacies within its network, according to Ajjarapu. Through the trading platform, independent pharmacies can see “up-to-the-minute” supply and pricing for pharmaceutical needs on a cost-efficient basis.

The Trxade Marketplace Platform uses a proprietary database and algorithms to identify pharmaceuticals likely to be in short supply. These are then delivered to independent pharmacies. The pharmacy’s total annual purchase costs can be reduced by up to 7-10%. No membership or transaction fees are required of them and they gain the ability to off-set negative insurance reimbursements.  The safe, secure, and easy web platform instantly connects to thousands of pharmacies with real-time information.

Integra Pharma Solutions is another Trxade division. Providing quality Rx products with significant savings, Integra Pharma Solutions is a pharmaceutical supplier for healthcare organizations of all sizes. Current healthcare markets serviced via Trxade include Government organizations, hospitals, independent pharmacies, and clinics across the nation. Trxade so far has over $800K+ in awards from the US Department of Veterans Affairs, 23K+ SKUs representing hundreds of manufacturers’ products, 60+ supply partners.

The company’s B2C operations are led via Bonum Health, which provides 24/7 access to Board-Certified Providers and Health Assessment Tools at a time when telehealth services are in high demand. Smart technology allows doctors and specialty providers to view vitals through special integrations like FitBit, iHealth, etc. Pending the outcomes of pilot programs, the company expects to make Bonum Health available nationwide.

Providing the sale of products directly to consumers, Trxade’s Community Specialty Pharmacy handles specialized care for patients suffering from chronic conditions. The focus is on rare or difficult to find medicines, including self-injectables, oral, and other supportive therapies.

This business model is proving beneficial for Trxade. At the end of Q2, the company showcased a 244% increase in revenue and a 74% increase in gross profit. Most of the growth can be attributed to an increase in sale and distribution of personal protective equipment (“PPE”) like N95 masks and sanitizing products, in response to the COVID-19 pandemic, through the Integra Pharma unit. When comparing numbers from June 30, 2020, against June 30, 2019, revenue increased from $5.6 million to $12.8million (“TTM”). Gross profits increased from $4.0 million to $6.2 million.

The main drivers of Trxade Group’s growth strategy are to increase the number of independent pharmacies serviced, increase the number of purchases per pharmacy, and increase the average amount of money spent per pharmacy.

For more information, visit the company’s website at www.TrxadeGroup.com

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom

• Actively executing its growth-by-acquisition strategy, building a portfolio of clinically proven, naturally formulated supplements
• The BergaMet NA brand is well-positioned for growth throughout North America with its proprietary 47% BPF formulations developed for cardiovascular health, women’s health, immune support, sports performance and recovery
• UBN subsidiary, with its KETONOMICS(R) proprietary formulation, is well-aligned with Grey Cloak’s corporate strategy to provide better lifestyles through superior health technology.
• KETONOMICS(R) is medical and scientific research that focuses on the field of brain and physiological metabolism which provides proprietary positions
• UBN has five unique formulation patents – one issued and four pending – targeting brain activity, focus, headache and cognitive behavior. These patents provide protection for proprietary formulas

Grey Cloak Tech (OTC: GRCK), through its growing portfolio of wholly owned subsidiaries, is engaged in the proprietary research and development of natural plant-based formulations, sales, and distribution of cardiovascular and neuro products. The company’s focus is to advance its market positions in the broader health industry through the unique assets and operations of its science-based BergaMet North America and Ultimate Brain Nutrients (“UBN”) subsidiaries and to offer better lifestyles through superior health technology

BergaMet North America

BergaMet NA is engaged in the sale and distribution of a full line of proprietary product formulations derived from the rare Citrus Bergamot SuperFruit(TM) called “bergamot.” Bergamot is native to Southern Italy and is naturally sourced and uniquely loaded with various antioxidant polyphenols. Thanks to this composition, bergamot supports and promotes overall wellness specific to cholesterol, cardiovascular and metabolic health with no known side effects.

BergaMet NA is the only Citrus Bergamot SuperFruit(TM) heart health supplement backed by 17 clinical studies. The BergaMet brand supplement boasts the highest quality and concentration of polyphenols and flavonoids available anywhere in the world. It is also the only bergamot supplement approved by the prestigious Accademia del Bergamotto of Italy. BergaMet NA is the only company authorized to manufacture, distribute and sell these products in the United States, Canada and Mexico.

Consumers are including the Citrus Bergamot SuperFruit(TM) in their everyday personal health programs. The clinically proven antioxidant provides benefits to tens of thousands of people daily.

The company’s line of products can be found at www.BergaMetNA.com, through Amazon, other online retailers and in doctors’ offices throughout the United States.

The BergaMet Advantage

BergaMet has been studied in 17 published clinical trials which reported results of lower LDL cholesterol, higher HDL cholesterol, lower triglycerides, lower blood pressure, lower blood glucose, increased arterial function, improved liver function and is effective as a complement to statin use.

Cardiovascular disease is the number one cause of death in the U.S. and worldwide, claiming nearly 18 million lives each year accounting for 31% of all global deaths. In the U.S., statins are one of the most commonly prescribed medicines for cardiovascular disease. The Centers for Disease Control estimates that 28% of American women and men over the age of 40 take a statin to lower the amount of cholesterol in the blood.

Taking aim at this market for cardiovascular care, BergaMet NA continues to advance the awareness of its medical-grade supplements and separate its formulation from competitors.

BergaMet NA products contain 47% BPF (bergamot polyphenolic fraction), while its closest competitors have only 38%. The company’s increased dosages (600-675mg vs 500mg) and 47% BPF are clinically proven to be more effective in improving heart health and metabolic syndrome.

BergaMet Citrus Bergamot SuperFruit(TM) supplements:

• Support healthy immune systems with powerful antioxidants and proprietary formulations
• Reduce cholesterol and support healthy glucose and blood pressure levels
• Are fully organic, vegan-friendly and dairy, gluten, soy and GMO-free
• Contain five key unique flavonoids that make up the most powerful 47% BPF (bergamot polyphenolic fraction) in the world, providing superior results compared to their competitors
• Have been clinically shown to increase arterial elasticity while reducing arterial and muscle inflammation

Ultimate Brain Nutrients

Grey Cloak’s Ultimate Brain Nutrients (“UBN”) subsidiary is a science-based company that develops unique, plant-based superior health technology neuro-products that improve brain health, including memory, cognition, focus and neuro-energy.

UBN’s KETONOMICS(R) proprietary formulations – targeting brain activity, focus, headache and cognitive behavior — provide multiple intellectual property license opportunities for monetizing the company’s portfolio.

License opportunities include multiple beverage formats, individual products, proprietary mixtures and other food platforms.

UBN has five unique formulation patents – one issued and four pending – targeting brain activity, focus, headache and cognitive behavior.

The UBN Advantage

UBN’s all-natural, sugar-free and caffeine-free proprietary formulations are the result of 20 years of scientific research and are positioned to provide consumer neuro-products that are natural brain solutions. UBN has filed for approval to the U.S. Food and Drug Administration (“FDA”) to make a Qualified Health Claim for its migraine formulation, tapping into consumer demands for healthy beverages that contribute to brain health, overall well-being and performance.

Over 50 million Americans consume unhealthy energy shots and drinks each day, while the neuro/energy market generates over $10 billion per year in revenue. Within this growing market, UBN is advancing its position to meet rising consumer demand for healthy, science-based options. The company’s KETONOMICS(R) proprietary formulations have been proven to naturally elevate brain energy and function, including memory, cognition and focus.

UBN’s KETONOMICS(R) supplementation has also been studied in sports physiology, with specific regard to its potential benefits for competitive performance and endurance.

Grey Cloak Executive Team

Kevin “Duke” Pitts, Director, President and Chief Operating Officer

• Started and built from the ground up two multi-million-dollar businesses, one of which grew into a Top 100 retailers in the U.S.
• Unique management skills led to the development of successful teams for 35 years
• Pioneered direct marketing for a Fortune 200 company, creating a 20% increase in targeted incremental sales
• Founded Einstein’s Hemp, which developed and brought to market one of the only odorless and tasteless water-soluble CBD products in the world
• Developed and implemented digital/guerrilla marketing strategies for public and private companies focused on long-term brand position and acquisition efforts
• Specialized in customer relationship management (“CRM”) tools for creating the best customer experiences
• Worked in publicly traded industries for 10 years, overseeing up to $20 million in annual marketing budgets

William “Bill” Bossung, Director, Chief Financial Officer

• 35 years of diverse experience in corporate finance, insurance and accounting
• 20 years of experience with IPOs focusing on audits, FINRA and SEC regulations
• Specializes in the formation of capital raising over $100 million, recently raising $12 million for Splash Beverage
• Specializes in upgrading penny stocks companies to the NYSE or Nasdaq
• Involved in 30+ companies transitioning from private to public identities
• Founded several companies, including BCF Technology Inc., which sold to Vertafore; managing partner at Bishop Equity Partners LLC; director at Splash Beverage Group; and director of finance at Chadmoore Wireless, where he licensed channels to Nextel for $162 million

Bill Croyle, Director, Private Investor and Accomplished Senior Executive

• More than 40 years of success in the IT, energy, manufacturing, telecommunications, venture capital and finance industries
• Broad expertise includes negotiating mergers and acquisitions, as well as service and delivery contracts
• Formerly was a founder, owner or executive of EnTX Group; Impact Legacy Partners; FB Oilfield Special Tools; and Western Energy Advisors

Dr. Gerald Haase, Chief Medical Officer

• Clinical professor of surgery at the University of Colorado, School of Medicine
• Actively involved in medical research and clinical trials for 35 years
• Received U-10 grant funding from the National Institutes of Health cooperative group clinical trials program, as well as U.S. Congressional funding for Cooperative Research and Development Agreements with the Department of Defense and NASA
• Was chairman of the Department of Pediatric Surgery at Children’s Hospital Colorado; consultant surgeon to the Department of the Army; vice-chairman of the Children’s Cancer Group, a cooperative research consortium of the National Cancer Institute; on the National Board of Directors of the American Cancer Society; a senior member of the Commission on Cancer of the American College of Surgeons; and a member of the editorial board of The Annals of Surgical Oncology
• Has published 180 scientific papers and is the inventor or co-inventor of 12 issued U.S. patents for micronutrient and phytonutrient therapy, with five pending patents
• Recipient of clinical research grants and contracts funded at a several million-dollar cumulative level
• Is an editorial reviewer for medical journals and a member of numerous professional societies, including the American Association for Cancer Research, International College of Surgeons, American Academy of Pediatrics, New York Academy of Sciences and American College of Physician Executives

For more information, visit the company’s website at www.HealthyExtractsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to GRCK are available in the company’s newsroom

• PACR bought nine parcels comprising 250 acres of land in Fraser Valley, British Columbia
• Share purchase agreement worth $1.5 million cash plus 3 million common shares
• PACR leverages genetic technology to produce high-yield cannabinoid-specific cultivars that thrive in B.C. climate

Pac Roots Cannabis (CSE: PACR), an innovative genetics-based cannabis company based in Canada, has just added 250 acres of premium Fraser Valley land to its portfolio. One of the most intensively farmed areas in Canada, the Fraser Valley generates the most significant farm income of any region in British Columbia. Boasting high-quality soils, a favorable climate, accessible water, and close proximity to educational and research institutions, this strategic acquisition will lend PACR added momentum in fulfilling its mission of leveraging genetics technology to cultivate specialized cannabinoid-specific strains for the production of top-quality cannabis products.

The company recently announced the closing of the share purchase agreement with the land’s shareholders that include 1088070 BC. LTD., Dave Jonkman and Norm Tapp. In exchange for the 250 acres of land, PACR agreed to pay an aggregate of $1.5 million in cash along with issuing an aggregate of 3 million common shares to the selling parties.

“The addition of such a substantial package of land to our portfolio is a major step for PacRoots. We are pleased to have the opportunity to add significant acreage with an acquisitional cost base of $9,600 per acre,” said PACR President and CEO Patrick Elliott. “This land has no zoning restrictions and is not situated within the Agricultural land reserve, which provides for infinite development possibilities.”

As part of its overall corporate strategy, PACR is dedicated to building a portfolio of valuable long-term income-producing and development assets. In addition to this latest acquisition of land, the company is also in the development stages of creating an indoor facility in Lake Country, B.C. along with already having acquired a 60% interest in a 100-acre joint venture hemp project in Rock Creek, British Columbia.

“Between the Fraser Valley and Rock Creek, B.C., which both rank at the top of the charts for outdoor agricultural producing regions in the Country, PacRoots is extremely well positioned for production and future development of Hemp and Cannabis infrastructure,” said PACR Board of Director Chad Clelland. “We are both privileged and proud to be involved in these exciting programs, which will undoubtedly add accretive value to our company and to our shareholders.”

Through its strategic genetic licensing partner, Phenome One, PACR has access to a large genetic library of cultivars that are suited for agricultural development on the west coast outdoor. Backed by testing and research over the past three years, the cultivar program has produced elite CBD and THC-rich cannabis strains that can thrive in wetter, milder outdoor conditions while generating exceptionally high yields.

“The lack of superior cannabis genetics, expertise and growing conditions have been a common headline that has plagued the industry in producing a premium product for the market,” Elliot further commented. “With the partnership with Phenome One and the access to their extensive genetic library, PacRoots is extremely well positioned to deliver the best in industry quality and throughput to the consumers with a pipeline of scalable development properties in the portfolio.”

Cannabis-based products are growing in popularity as their use becomes increasingly accepted across all demographics. The ability to deliver strains varying in cannabinoids like THC and CBD is gaining importance due to increased consumer awareness, necessitating the need for cultivators in the sector to enhance and differentiate cannabis products through their genetic makeup. PACR’s pioneering approach towards producing premium-grade cannabis strains, along with its portfolio of pristine land and production assets, is positioning the company as a future leader in the global cannabis industry.

For more information, visit the company’s website at www.PacRoots.ca.

NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom